Glenmark Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 26, 2025. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals held its 47th AGM on September 26, 2025, via video conferencing, chaired by CMD Mr. Glenn Saldanha, with 59 shareholders present through VC. All 8 resolutions were passed with overwhelming shareholder approval, including adoption of standalone and consolidated financial statements for FY25, declaration of a dividend of Rs. 2.50 per equity share, re-appointment of Mrs. Cherylann Pinto, and appointment of Walker Chandiok & Co. LLP as statutory auditors. A new independent director, Ms. Patricia Andrews, was appointed via special resolution. Voting results showed support of over 99% on most resolutions, with the lowest approval at 99.12% for appointing Rauthan & Associates as secretarial auditor. Total valid votes polled were around 23.2 crore equity shares, representing about 82% of outstanding shares.
Shareholders have approved a Rs. 2.50 per share dividend for FY25 and endorsed the company's governance, audit, and board changes with near-unanimous support. The strong voting turnout and high approval margins signal shareholder confidence in management, with no negative surprises expected to move the stock.